Emmanuel Petricoin

15PUBLICATIONS
185CO-AUTHORS
Molecular targetsImmunogenetics (incl. genetic immunology)Predictive and prognostic markersCancer cell biologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 09, 2026
Acquisition of resistance to RAS inhibition is associated with the upregulation of macropinocytosis through both PI3K-dependent and -independent signaling.

|Oct 10, 2025
The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer.

Erica V Carballo, Paula Gonzalez-Ericsson, Brian D Lehmann

|Sep 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer.

Priya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp

|Sep 04, 2025
Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.

Emmanuel F Petricoin, Denise M Wolf, Christina Yau

|Aug 15, 2025
HuR-Regulated Extracellular Vesicles Promote Endothelial Cell Remodeling in Pancreatic Cancer.

Jennifer M Finan, Yifei Guo, Alexandra Q Bartlett

|Jul 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.

Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp

Pageof 3

Frequent Collaborators

5 joint publications

Kirsten L Bryant

5 joint publications

Clint A Stalnecker

5 joint publications

Adrienne D Cox

4 joint publications

Rosa I Gallagher